Table 1.
Characteristics of monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SM), and multiple myeloma (MM) patients.
| Description | HV | Myeloproliferative neoplasms | MGUS | SM | MM |
|---|---|---|---|---|---|
| Nbr of patients (total) | 46 | 40 | 68 | 6 | 74 |
| Nbr with available biological data | 0 | 40 | 59 | 6 | 68 |
| Nbr with available sialylation data for mc IgG | 0 | 0 | 68 | 6 | 74 |
| Nbr with available sialylation data for pc IgG | 46 | 40 | 68 | 6 | 68 |
| Nbr with available cytokines expression data | 9 | 0 | 34 | 5 | 25 |
| Male sex (%) | NA | 54.2% | 55.9% | 83.3% | 60.3% |
| Age (years) | |||||
| Median | NA | 66.2 | 67.0 | 67.1 | 63.6 |
| Range | NA | 33.0–95.0 | 31.0–96.9 | 40.0–84.0 | 45.7–86.5 |
| Mc IgG (g/L) | |||||
| Median | NA | NA | 12.0 | 21.8 | 18.5 |
| Range | NA | NA | 4.0–28.9 | 13.5–67.0 | 8.5–68.0 |
| β2-Microglobulin (mg/L) | |||||
| Median | ND | ND | 2.5 | 4.9 | 3.1 |
| Range | ND | ND | 1.4–10.1 | 2.1–5.8 | 1.3–12.1 |
| Leukocytes (109/L) | |||||
| Median | ND | 9.3 | 7.1 | 8.5 | 5.1 |
| Range | ND | 2.8–41.0 | 0.2–34.3 | 6.1–29.2 | 0.6–19.0 |
| Hemoglobin (g/dL) | |||||
| Median | ND | 15.6 | 13.3 | 12.8 | 10.9 |
| Range | ND | 7.9–22.4 | 8.7–16.2 | 6.9–15.5 | 7.3–15.5 |
| Platelets (109/L) | |||||
| Median | ND | 437.5 | 224.0 | 217.5 | 202.0 |
| Range | ND | 67.0–1,851.0 | 38.0–580.0 | 178.0–309.0 | 15.0–529.0 |
| ISS stage III (%) | ND | ND | ND | 20% | 32.7% |
| DSS stage III (%) | ND | ND | ND | 0% | 44.6% |
Nbr, number of patients; HV, healthy volunteers; NA, not available; ND, not determined; ISS, International Staging System; DSS, Durie–Salmon Staging.